AnderMed Files for HKEX IPO, Innovative Medical Consumables Provider Ranking 2nd in China by Product Registrations

NewTimeSpace News: Shandong Ande Healthcare Apparatus Co., Ltd. (AnderMed) submitted a listing application to the Hong Kong Stock Exchange on May 15, 2026, with CSC International serving as the sole sponsor.

As a leading innovative medical consumables provider in China, the company adheres to an innovation-driven strategy and delivers comprehensive, high-quality medical consumables solutions to medical institutions. Supported by integrated capabilities covering R&D, product registration, manufacturing, quality management and commercialization, AnderMed has built a competitive and diversified product portfolio, including (i) drug delivery, (ii) vascular access, (iii) blood specimen collection, and (iv) others, mainly interventional therapy products, surgical supplies and medical imaging consumables. Its products serve a wide range of clinical departments and application scenarios.

According to Frost & Sullivan, the company ranks second in China by the number of NMPA medical consumables registrations as of the latest practicable date. It is also one of the global enterprises with the most comprehensive lineup of vascular access product registrations. In terms of 2025 revenue, its drug delivery products rank second in the Chinese market.

In addition, the company’s polyurethane indwelling needle was awarded the title of National Manufacturing Single Champion Product in 2025. Going forward, upholding the philosophy of innovation-driven development, premium quality, cost leadership and optimal value for customers, the company strives to become a world-leading medical consumables supplier.